top of page

Mesa%252520Verde%252520logo%2525201_edit

MESA VERDE

VENTURE PARNERS

Search

- May 6, 2021

Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

Interim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel data (57% ORR vs. ~30% ORR historical single-agent paclitaxel)
In a preclinical study of cirmtuzumab added to high-grade serous ovarian cancer cell lines, cirmtuzumab demonstrated single agent activity and enhanced the anti-proliferative effect of commonly used chemotherapies
Oncternal appointed Chase Leavitt as General Counsel
Oncternal presenting clinical updates on cirmtuzumab in MCL/CLL and TK216 in Ewing sarcoma at the ASCO Annual Meeting in June 2021
Management to host webcast today at 5:00 pm ET

https://investor.oncternal.com/news-releases/news-release-details/oncternal-provides-business-update-and-announces-first-quarter-0

Recent Posts

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- - Commenced exclusive distribut

Equillium Announces Three Abstracts Accepted for Presentation at the 104th AAI Annual Meeting

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients https://

MatriSys Bioscience Names Joyce Rico as Chief Medical Officer

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce Rico, MD, MBA, FAAD, as Chief Medical Officer. Dr. Rico has over

bottom of page